Ratings Foghorn Therapeutics Inc.

Equities

FHTX

US3441741077

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
5.99 ^USD	-1.96%		+14.53%	-7.13%

16/04	Foghorn Therapeutics Names Kristian Humer CFO	MT
16/04	Foghorn Therapeutics Inc. Appoints Kristian Humer as Chief Financial Officer	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
FOGHORN THERAPEUTICS INC.	-7.13%	260M	D+
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+8.96%	101B	B+
ARGENX SE	+4.40%	23.07B	B
BIONTECH SE	-12.15%	22.23B	B+
GENMAB A/S	-4.36%	18.05B	A-
WUXI APPTEC CO., LTD.	-39.98%	17.18B	A-
BEIGENE, LTD.	-10.04%	16.94B	B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.07B	C+
SAREPTA THERAPEUTICS, INC.	+38.61%	12.35B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes